Idiopathic interstitial pneumonia
| lolo |
lolo2 |
lolo3
|
| koko1 |
koko2 |
koko3
|
| lolo |
lolo2 |
lolo3
|
| koko1 |
koko2 |
koko3
|
| Class I
|
| "1. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.(Level of Evidence: A)"
|
| "2. In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.(Level of Evidence: A)"
|
| Risk category
|
LDL goal, mg/dL
|
Non-HDL goal, mg/dL
|
| CHD and CHD risk equivalent (10 year risk for CHD is >20%)
|
< 100
|
< 130
|
| Multiple (2+) risk factor (10 year risk for CHD is <20%)
|
< 130
|
< 160
|
| 0-1 risk factors
|
< 160
|
< 190
|
ATP III LDL cholesterol and Non-HDL cholesterol goals [1]
| Class I
|
| "1. Individuals with LDL–C ≥190 mg/dL or triglycerides ≥500 mg/dL should be evaluated for secondary causes of hyperlipidemia.(Level of Evidence: B)"
|
"2. Adults ≥21 years of age with primary LDL–C ≥190 mg/dL should be treated with statin therapy (10-year ASCVD risk estimation is not required):
- Use high-intensity statin therapy unless contraindicated.
- For individuals unable to tolerate high-intensity statin therapy, use the maximum tolerated statin intensity.(Level of Evidence: B)"
|
References